Watch CVKD. Know when insiders buy.
One email the day a filing lands. Free.
CVKD
Cadrenal Therapeutics, Inc.
1.18
−0.01 −0.84%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
35
FLAG · shorts 35
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$11.5MNET CASH $1.8M52W 1.18 – 14.20SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.3M | −$3.3M | — | -1.14 | −$2.2M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$2.5M | −$2.5M | — | -1.04 | −$3M | — | — | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.1M | −$3M | — | -1.41 | −$2.6M | $0 | −$2.6M | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$2.7M | −$2.7M | — | -1.31 | −$2.4M | $2K | −$2.4M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$3.7M | −$3.7M | — | -1.87 | −$3M | $0 | −$3M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$3.9M | −$3.8M | — | -2.09 | −$4.6M | $3K | −$4.7M | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.3M | −$4.2M | — | -3.49 | −$1.8M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$2.5M | −$2.4M | — | -2.18 | −$2.2M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$2.5M | −$2.4M | — | -2.24 | −$1.5M | — | — | Aug 11 |
| Q1 2024 · Mar 31 | — | — | — | −$1.8M | −$1.7M | — | -1.56 | −$1.8M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.3M | −$1.1M | — | -0.73 | −$694K | $0 | −$694K | Mar 13 |
| Q3 2023 · Sep 30 | — | — | — | −$1.1M | −$1M | — | -1.01 | −$628K | $1 | −$628K | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$13.5M | −$13.2M | — | -6.64 | −$12.6M | $5K | −$12.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$11M | −$10.7M | — | -8.73 | −$7.4M | $7K | −$7.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$7.6M | −$8.4M | — | -9.29 | −$3.5M | $3K | −$3.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$2.7M | −$6.7M | — | -0.85 | −$1.2M | $2K | −$1.2M | — | — |
Every number comes from Cadrenal Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.